3
Clinical Trials associated with Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University) / Not yet recruitingPhase 2IIT Prospective clinical study of the safety and efficacy of anti-B7-H3 CAR T cells in the treatment of relapsed, refractory acute myeloid leukemia
A Single-Arm, Open-Label Study to Evaluate Safety and Efficacy of B7H3 or HBsAg Targeting CAR-T in Treating Advanced Hepatocellular Carcinoma
This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.
A Single-Arm, Open-Label Study to Evaluate Safety and Efficacy of Fully Human B7H3 CAR-T in Treating Patients With Recurrent Malignant Ovarian Cancer
This is single center, open-label phase I, non-randomized study which will enroll patients with recurrent advanced ovarian cancer to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T cells (fhB7H3.CAR-Ts) via using a '3+3+3' dose escalation design. In the dose expansion cohort, six patients will be enrolled to further assess their efficacy with the optimal dosage.
100 Clinical Results associated with Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University)
100 Translational Medicine associated with Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University)
100 Patents (Medical) associated with Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University)
100 Deals associated with Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University)